Evidence map›Paper›PMID 19435463›Full record

ArticleBioscience reports2009

ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins.

Shaoyi Huang, In Soon Chang, Wenbo Lin, Wenduo Ye, Robert Z Luo, Zhen Lu, Yiling Lu, Ke Zhang, Warren S-L Liao, Tao Tao and 3 more

Open access · greenAbstract read
In one paragraph

Article in Bioscience reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Shaoyi HuangDepartment of Experimental Therapeutics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
In Soon Chang
Wenbo Lin
Wenduo Ye
Robert Z Luo
Zhen Lu
Yiling Lu
Ke Zhang
Warren S-L Liao
Tao Tao
Robert C Bast
Xiaomin Chen
Yinhua Yu
Xiamen University · CNObstetrics and Gynecology Hospital of Fudan University · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
ROLE OF ALLELIC IMBALANCE IN OVARIAN CANCER PROGRESSIONP01CA064602 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI JAFFE, ROBERT B · 1996 to 2005
$11.3M
NOEY2--AN IMPRINTED BREAST CANCER SUPPRESSOR GENER01CA080957 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, YINHUA · 1999 to 2008
$1.4M
BIOCHEMICAL STUDIES OF STAT NUCLEAR LOCALIZATIONR01GM068556 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, XIAOMIN · 2004 to 2008
$1.3M
NCI NIH HHS CA 64602NCI NIH HHS CA 80957NCI NIH HHS P01 CA064602NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS R01 CA080957NIGMS NIH HHS GM68556NIGMS NIH HHS R01 GM068556
6 · The paper itself

Abstract

ARHI (aplasia Ras homologue member I; also known as DIRAS3) is an imprinted tumour suppressor gene, the expression of which is lost in the majority of breast and ovarian cancers. Unlike its homologues Ras and Rap, ARHI functions as a tumour suppressor. Our previous study showed that ARHI can interact with the transcriptional activator STAT3 (signal transducer and activator of transcription 3) and inhibit its nuclear translocation in human breast- and ovarian-cancer cells. To identify proteins that interact with ARHI in nuclear translocation, in the present study, we performed proteomic analysis and identified several importins that can associate with ARHI. To further explore this novel finding, we purified 10 GST (glutathione transferase)-importin fusion proteins (importins 7, 8, 13, beta1, alpha1, alpha3, alpha5, alpha6, alpha7 and mutant alpha1). Using a GST-pulldown assay, we found that ARHI can bind strongly to most importins; however, its binding is markedly reduced with an importin alpha1 mutant that contains an altered NLS (nuclear-localization signal) domain. In addition, an ARHI N-terminal deletion mutant exhibits greatly reduced binding to all importins compared with wild-type ARHI. In nuclear-import assays, the addition of ARHI blocked nuclear localization of phosphorylated STAT3. ARHI also inhibits the interaction of Ran-importin complexes with GFP (green fluorescent protein) fusion proteins that contain an NLS domain and a beta-like import receptor-binding domain, thereby blocking their nuclear localization. By conducting GST-pulldown assays, we found that ARHI could compete for Ran-importin binding. Thus ARHI-induced disruption of importin-binding to cargo proteins, including STAT3, could serve as an important regulatory mechanism that contributes to the tumour-suppressor function of ARHI.

Indexed as

Active Transport, Cell NucleusBlotting, WesternCell Line, TumorCell NucleusGenes, Tumor SuppressorGenomic ImprintingGlutathione TransferaseGreen Fluorescent ProteinsHeLa CellsHumansKaryopherinsMicroscopy, FluorescenceNuclear Localization SignalsProtein BindingProtein TransportProteomicsDIRAS3 protein, humanGlutathione TransferaseGreen Fluorescent ProteinsKaryopherinsNuclear Localization Signalsran GTP-Binding ProteinRAN protein, humanRecombinant Fusion Proteinsrho GTP-Binding ProteinsSTAT3 Transcription Factor

Identifiers

PMID19435463
PMCPMC2974631
OpenAlexW2046390289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.